538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Tirzepatide offers a powerful new treatment option for Type 2 Diabetes Mellitus, particularly for those struggling to achieve adequate glycemic control with existing therapies. The successful completion of this Phase …
This real-world study provides compelling evidence that treatment persistence is a critical determinant for maximizing the comprehensive benefits of Tirzepatide across the spectrum of Cardio-Metabolic-Kidney Syndrome.…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
This study provides compelling evidence that GLP-1 Receptor Agonists offer significant protective benefits beyond glycemic control, extending to both systemic and ocular vascular health in a high-risk population. Thes…
The successful outcome of this trial could represent a paradigm shift in managing the complex interplay of Type 1 Diabetes and obesity. If Tirzepatide proves safe and effective, it could offer a novel therapeutic opti…
This study is crucial for understanding Tirzepatide's performance in patient groups often excluded from or underrepresented in randomized controlled trials. If successful, it could provide valuable evidence supporting…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This study provides crucial evidence for policymakers, demonstrating the significant economic and health benefits of investing in comprehensive obesity management programs. By integrating more nuanced data on T2D prog…
This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting it may induce hypercapnia in susceptible individuals even with normal lung function. This finding underscores the …
The meta-analysis revealed significant improvements in metabolic parameters among kidney transplant recipients treated with GLP-1 RAs. Patients experienced a mean weight loss of 4.5 kg (p<0.001) and a reduction in HbA…
Preserving lean body mass during weight loss is crucial for maintaining metabolic health, physical strength, and preventing conditions like sarcopenia (age-related muscle loss). If successful, this study could provide…
This study represents a pivotal advancement in the treatment landscape for obstructive sleep apnea, offering a highly effective pharmacological approach that directly addresses a major underlying cause: obesity. The s…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necro…
This study provides crucial evidence supporting the economic value of Tirzepatide for a complex patient population suffering from HFpEF and obesity. These findings could significantly influence clinical guidelines, fo…
This study provides a robust, integrated safety profile for widely used GLP-1 RAs, offering a more complete picture than individual studies alone. Understanding these comprehensive safety data is crucial for informing…
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorabl…
This comprehensive meta-analysis provides compelling real-world evidence that GLP-1-based therapies offer substantial benefits beyond glycemic control and cardiovascular protection, extending to critical limb outcomes…
This study provides compelling real-world evidence that tirzepatide offers superior benefits in preventing the progression of cardiovascular-kidney-metabolic syndrome compared to other GLP-1 receptor agonists. The sig…
This study provides critical insights into the pharmacovigilance of drug-associated ketoacidosis, highlighting specific drug classes that warrant increased clinical vigilance. The strong signal for SGLT2 inhibitors re…
The widespread presence of unidentified impurities in commonly used compounded medications poses a significant patient safety risk, potentially altering the drug's efficacy, stability, or causing unforeseen adverse ef…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
This study is significant because Tirzepatide could offer a novel therapeutic strategy for managing endometrial intra-epithelial neoplasia (EIN) and early-stage endometrial cancer, particularly in obese women. Given t…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This comprehensive toxicological profile provides a crucial foundation for understanding the safety landscape of existing anti-diabetic drugs and informing the development of safer next-generation therapies. The ident…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
This research highlights a novel, non-glycemic benefit of Tirzepatide, suggesting its potential beyond glucose and weight management. The ability of Tirzepatide to significantly enhance angiogenesis and improve blood …
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
This study provides crucial evidence for clinicians and patients, highlighting the distinct advantages of metabolic and bariatric surgery in achieving more profound and sustained improvements in cardiometabolic risk p…
This case highlights a potential adverse dermatological reaction to tirzepatide, suggesting that GLP-1/GIP receptor agonists might, in rare instances, trigger or exacerbate autoimmune conditions like psoriasis. This o…
This comprehensive review underscores Semaglutide's robust potential as an effective pharmacological intervention for chronic weight management in non-diabetic adults. The consistent and substantial weight loss, coupl…
These findings provide compelling evidence that tirzepatide can fundamentally alter the disease classification for a significant number of individuals with obesity and overweight, moving them into lower-risk BMI categ…
Tirzepatide not only facilitates significant weight loss but also enables a substantial proportion of individuals with obesity to achieve healthier BMI categories, which is directly associated with profound improvemen…
This review highlights Tirzepatide's potential as a valuable adjunct therapy for managing the complex challenges of Type 1 Diabetes complicated by overweight or obesity. The dual benefits of improved glycemic control …
This study is highly significant because it could establish Tirzepatide as a novel therapeutic agent for directly improving cardiovascular health in overweight and obese individuals with existing Coronary Artery Disea…
This study provides crucial dose-response data for NNC0519-0130, suggesting it could be a highly effective once-weekly treatment for Type 2 Diabetes. The observed significant reductions in HbA1c and body weight, coupl…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…